Amryt Announces New Patent for Mycapssa®

Provided By Globe Newswire

Last update: Nov 30, 2022

Amryt Announces New Patent for Mycapssa®

DUBLIN, Ireland, and Boston MA, November 30, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces an update regarding the patents for its product Mycapssa® (octreotide).